Mayer L - Search Results

1

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. Targan SR, et al. Among authors: mayer l. N Engl J Med. 1997 Oct 9;337(15):1029-35. doi: 10.1056/NEJM199710093371502. N Engl J Med. 1997. PMID: 9321530 Free article. Clinical Trial.

2

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Present DH, et al. Among authors: mayer l. N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804. N Engl J Med. 1999. PMID: 10228190 Free article. Clinical Trial.

3

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Among authors: mayer l. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.

4

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Sands BE, et al. Among authors: mayer l. Inflamm Bowel Dis. 2001 May;7(2):83-8. doi: 10.1097/00054725-200105000-00001. Inflamm Bowel Dis. 2001. PMID: 11383595 Clinical Trial.

5

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Levine B, et al. Among authors: mayer l. N Engl J Med. 1990 Jul 26;323(4):236-41. doi: 10.1056/NEJM199007263230405. N Engl J Med. 1990. PMID: 2195340 Free article.

6

Extraintestinal manifestations in patients with diverticulitis.

Klein S, Mayer L, Present DH, Youner KD, Cerulli MA, Sachar DB. Klein S, et al. Among authors: mayer l. Ann Intern Med. 1988 May;108(5):700-2. doi: 10.7326/0003-4819-108-5-700. Ann Intern Med. 1988. PMID: 3358570

7

The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease.

Akolkar PN, Gulwani-Akolkar B, Lin XY, Zhou Z, Daly M, Katz S, Levine J, Present D, Gelb B, Desnick R, Mayer L, Silver J. Akolkar PN, et al. Among authors: mayer l. Am J Gastroenterol. 2001 Apr;96(4):1127-32. doi: 10.1111/j.1572-0241.2001.03758.x. Am J Gastroenterol. 2001. PMID: 11316159

8

Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2.

Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L. Cunningham-Rundles C, et al. Among authors: mayer l. N Engl J Med. 1994 Oct 6;331(14):918-21. doi: 10.1056/NEJM199410063311405. N Engl J Med. 1994. PMID: 8078552 Free article. No abstract available.

9

Inhibition of HIV-1 productive infection in hepatoblastoma HepG2 cells by recombinant tumor necrosis factor-alpha.

Banerjee R, Sperber K, Pizzella T, Mayer L. Banerjee R, et al. Among authors: mayer l. AIDS. 1992 Oct;6(10):1127-31. doi: 10.1097/00002030-199210000-00010. AIDS. 1992. PMID: 1466843

10

The role of the epithelial cell in immunoregulation: pathogenetic and therapeutic implications.

Mayer L. Mayer L. Mt Sinai J Med. 1990 Oct;57(5):279-82. Mt Sinai J Med. 1990. PMID: 2096275 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,154 results

Search Page

Filters